BioDelivery Sciences International (NASDAQ:BDSI) Given New $8.00 Price Target at LADENBURG THALM/SH SH

BioDelivery Sciences International (NASDAQ:BDSI) had its price objective boosted by LADENBURG THALM/SH SH from $6.00 to $8.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently commented on BDSI. ValuEngine upgraded BioDelivery Sciences International from a strong sell rating to a sell rating in a research report on Tuesday, October 29th. BidaskClub cut BioDelivery Sciences International from a strong-buy rating to a buy rating in a research report on Friday, November 8th. Janney Montgomery Scott reiterated a buy rating on shares of BioDelivery Sciences International in a research report on Wednesday. Finally, William Blair reiterated a buy rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $6.50.

Shares of BDSI traded up $0.23 during midday trading on Wednesday, reaching $6.23. 3,786,700 shares of the stock were exchanged, compared to its average volume of 918,798. The business’s 50-day moving average price is $5.22 and its 200 day moving average price is $4.59. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.09. BioDelivery Sciences International has a twelve month low of $2.80 and a twelve month high of $6.45. The company has a market capitalization of $522.82 million, a price-to-earnings ratio of -8.53 and a beta of 0.39.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.34. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. The business had revenue of $30.31 million for the quarter, compared to analysts’ expectations of $28.86 million. As a group, equities research analysts expect that BioDelivery Sciences International will post -0.05 earnings per share for the current fiscal year.

In related news, Director Mark A. Sirgo sold 157,177 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $4.79, for a total value of $752,877.83. Following the transaction, the director now owns 1,874,637 shares in the company, valued at approximately $8,979,511.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.29, for a total value of $34,320.00. Following the completion of the transaction, the director now owns 588,754 shares in the company, valued at approximately $2,525,754.66. The disclosure for this sale can be found here. Insiders sold a total of 373,364 shares of company stock worth $1,859,559 in the last 90 days. 8.94% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. BTR Capital Management Inc. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at approximately $47,000. Cutter & CO Brokerage Inc. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at approximately $60,000. Nisa Investment Advisors LLC purchased a new stake in BioDelivery Sciences International in the 3rd quarter valued at approximately $148,000. Resources Investment Advisors LLC. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at approximately $172,000. Finally, Acadian Asset Management LLC boosted its holdings in BioDelivery Sciences International by 348.9% in the 2nd quarter. Acadian Asset Management LLC now owns 58,243 shares of the specialty pharmaceutical company’s stock valued at $271,000 after purchasing an additional 45,269 shares in the last quarter. Hedge funds and other institutional investors own 66.89% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Recommended Story: Are analyst ratings accurate?

The Fly

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.